BIIB110
/ Biogen, AliveGen
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 12, 2025
ALG-801 demonstrates superior therapeutic efficacy in sugen-hypoxia model of pulmonary hypertension
(ERS 2025)
- "These findings demonstrate that in SuHx PAH model, ALG-801 has a significantly better efficacy than sildenafil or sotatercept. ALG-801 holds a promising potential for treating pulmonary hypertension."
Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • ACVR2A • TGFB1
January 07, 2025
AliveGen Receives FDA Orphan Drug Designation for ALG-801 for Pulmonary Arterial Hypertension
(Businesswire)
- "AliveGen USA Inc...announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for the treatment of pulmonary arterial hypertension (PAH), a rare, serious, and life-threatening condition characterized by high blood pressure in the lung arteries that can lead to right-sided heart failure."
Orphan drug • Pulmonary Arterial Hypertension
April 05, 2024
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ALG-801 in Healthy Postmenopausal Women
(ANZCTR)
- P1 | N=32 | Completed | Sponsor: AliveGen USA, Inc. | Not yet recruiting ➔ Completed
Trial completion • Osteoporosis
1 to 3
Of
3
Go to page
1